Agena Bioscience expands ultrasensitive somatic mutation detection technology Agena Bioscience.
Agena Bioscience expands ultrasensitive somatic mutation detection technology Agena Bioscience, Inc., which acquired the Bioscience business of Sequenom recently, Inc Click to read more . The first panel offered this full year, the UltraSEEK Oncogene Panel, uses 40 nanograms of input DNA to interrogate 26 driver mutations in 12 critical oncogenes. Tumors harbor many cells with differing genetic mutations. While some of the cells might contain mutations that confer resistance to targeted inhibitors, they may compose such a miniscule element of the tumor these cells aren’t detected using standard genotyping and sequencing methodologies.
But patients frequently question if kidneys from different donors are of similar quality and anticipated longevity. Related StoriesStudy suggests mix of MMF and CNIs can drive back rare lymphomaDonor and patient age more important in determining kidney transplant successSleep deprivation can influence result of stem cell transplantation, study findsTo investigate, John Gill, MD and his colleagues analyzed the survival of kidneys from donors of different age ranges that were transplanted into recipients of different age ranges. Their study included data from all adult kidney transplants from living donors that were performed in the United States from January 1988 to December 2003, with follow-up through September 2007.